 This large-scale study aims for the rapid roll-out of TDFFTC to individuals at high risk of HIV, who will comprise mostly gay and bisexual men GBM but will also include small numbers of heterosexuals, people who inject drugs, and transgender men and women. The drug will be used according to existing Australasian Society for HIV, Viral Hepatitis and Sexual Health ASHM HIV PrEP Clinical Guidelines. 